Fig. 3
Identification of candidate drivers in WB1P-Myc tumors using comparative oncogenomics. a, b Genome-wide RUBIC analysis of CNV profiles of WB1P tumors (a) and WB1P-Myc tumors (b). Significant amplifications and deletions are marked by light red and blue columns, respectively. c Genomic instability of WB1P and WB1P-Myc tumors. Scores for spleen samples from WB1P mice are shown as reference; ****P < 0.0001 (two-sided Mann–Whitney U-test). Boxes extend from the third (Q3) to the first (Q1) quartile (interquartile range, IQR), with the line at the median; whiskers extend to Q3 + 1.5 × IQR and to Q1 − 1.5 × IQR. See Materials and Methods for more details. d Flowchart illustrating the comparative oncogenomics analysis pipeline used for the identification of additional cancer driver genes. e Chromosome 3 RUBIC analysis of the combined CNV profiles of the tumors from germline and somatic mouse models overexpressing Myc in the mammary gland. Significant amplifications are marked by light red columns. Genes residing in the minimal amplicon of chromosome 3 are shown. Cross-species candidate genes surviving filter criteria are colored in red. f Chromosome 1 RUBIC analysis of the CNV profiles of human TNBC. Significant amplifications are marked by light red columns. Orthologs of the genes shown in e are shown. Cross-species candidate genes surviving filter criteria are colored in red
